Report of Foreign Issuer (6-k)
April 22 2019 - 10:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of April 2019
001-37353
(Commission File Number)
BIONDVAX PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
Jerusalem BioPark
Hadassah Ein Carem,
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
____
Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
On
April 22, 2019, BiondVax Pharmaceuticals Ltd. (“BiondVax”) issued a press release announcing a €4 million extension
to its 2017 financing agreement with European Investment Bank (EIB) in support of the ongoing pivotal Phase 3 clinical trial of
BiondVax’s M-001 Universal Influenza Vaccine candidate.
A
copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: April 22, 2019
|
By:
|
/s/ Ron Babecoff
|
|
|
Ron Babecoff
|
|
|
Chief Executive Officer
|
2
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Jun 2024 to Jul 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Jul 2023 to Jul 2024